598 related articles for article (PubMed ID: 18818047)
1. Reversal effect of substituted 1,3-dimethyl-1H-quinoxalin-2-ones on multidrug resistance in adriamycin-resistant K562/A02 cells.
Sun LR; Li X; Cheng YN; Yuan HY; Chen MH; Tang W; Ward SG; Qu XJ
Biomed Pharmacother; 2009 Mar; 63(3):202-8. PubMed ID: 18818047
[TBL] [Abstract][Full Text] [Related]
2. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
[TBL] [Abstract][Full Text] [Related]
3. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
4. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
5. Reversal effects of hyaluronan oligosaccharides on adriamycin resistance of K562/A02 cells.
Cui X; Zhou S; Xu H; Zhao T; Liu A; Guo X; Wang F
Anticancer Drugs; 2009 Oct; 20(9):800-6. PubMed ID: 19606017
[TBL] [Abstract][Full Text] [Related]
6. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by milbemycin compounds in adriamycin-resistant human breast carcinoma (MCF-7/adr) cells.
Xiang W; Gao A; Liang H; Li C; Gao J; Wang Q; Shuang B; Zhang J; Yan Y; Wang X
Toxicol In Vitro; 2010 Sep; 24(6):1474-81. PubMed ID: 20656007
[TBL] [Abstract][Full Text] [Related]
7. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
8. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells.
Ji BS; He L
J Pharm Pharmacol; 2007 Jul; 59(7):1011-5. PubMed ID: 17637197
[TBL] [Abstract][Full Text] [Related]
9. Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycin-resistant K562/A02 cells.
Shi YQ; Qu XJ; Liao YX; Xie CF; Cheng YN; Li S; Lou HX
Eur J Pharmacol; 2008 Apr; 584(1):66-71. PubMed ID: 18304528
[TBL] [Abstract][Full Text] [Related]
10. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
11. Reversal effects of droloxifene on multidrug resistance in adriamycin-resistant K562 cell line.
Li J; Xu LZ; Yao JJ; Guo WJ; Xia P; Chen Y
Acta Pharmacol Sin; 2001 Nov; 22(11):1023-7. PubMed ID: 11749795
[TBL] [Abstract][Full Text] [Related]
12. Modulation of P-glycoprotein activity by the substituted quinoxalinone compound QA3 in adriamycin-resistant K562/A02 cells.
Sun LR; Zhong JL; Cui SX; Li X; Ward SG; Shi YQ; Zhang XF; Cheng YN; Gao JJ; Qu XJ
Pharmacol Rep; 2010; 62(2):333-42. PubMed ID: 20508289
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of substituted dibenzo[c,e]azepine-5-ones as P-glycoprotein-mediated multidrug resistance reversal agents.
Tang X; Gu X; Ren Z; Ma Y; Lai Y; Peng H; Peng S; Zhang Y
Bioorg Med Chem Lett; 2012 Apr; 22(8):2675-80. PubMed ID: 22450134
[TBL] [Abstract][Full Text] [Related]
14. Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTπ activity.
Song YN; Guo XL; Zheng BB; Liu XY; Dong X; Yu LG; Cheng YN
Toxicol In Vitro; 2011 Jun; 25(4):937-43. PubMed ID: 21402141
[TBL] [Abstract][Full Text] [Related]
15. The synergistic reversal effect of multidrug resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells.
Shen J; Zhang W; Wu J; Zhu Y
Int J Hyperthermia; 2008 Mar; 24(2):151-9. PubMed ID: 18283591
[TBL] [Abstract][Full Text] [Related]
16. Reversal effects of two new milbemycin compounds on multidrug resistance in MCF-7/adr cells in vitro.
Gao A; Liang H; Wang X; Zhang X; Jing M; Zhang J; Yan Y; Xiang W
Eur J Pharmacol; 2011 Jun; 659(2-3):108-13. PubMed ID: 21458446
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Li GY; Liu JZ; Zhang B; Wang LX; Wang CB; Chen SG
Biomed Pharmacother; 2009 Sep; 63(8):566-70. PubMed ID: 19095404
[TBL] [Abstract][Full Text] [Related]
18. Sensitization and apoptosis augmentation of K562/ADM cells by anti-multidrug resistance gene peptide nucleic acid and antisense oligodeoxyribonucleotide.
Wei HL; Wu YJ; Jing T; Bai DC; Ma LF
Acta Pharmacol Sin; 2003 Aug; 24(8):805-11. PubMed ID: 12904281
[TBL] [Abstract][Full Text] [Related]
19. The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.
Lü S; Chen Z; Yang J; Chen L; Zhou H; Xu X; Li J; Han F; Wang J
Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e123-31. PubMed ID: 19254348
[TBL] [Abstract][Full Text] [Related]
20. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
Chen G; Waxman DJ
J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
